Taipei Exchange exchange. Sector: Healthcare. Industry: Biotechnology. Location Taiwan, Tainan City.

Sunmax Biotechnology Co., Ltd. [4728.TWOTaiwan

147.5USD0.5 (+0.34%)

• At close Thu Oct 06 2022

240,653,711 USD
BETA (5y)



for 5 years



for 3 years



for 2 years



for 1 year



for this year

About Sunmax Biotechnology Co., Ltd.

Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets medical-grade collagen-based medical devices in Asia. The company offers Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes; and dermal fillers, such as Sunmax collagen implant I-Plus and Sumax collagen implant I for the correction of facial defects, such as the fill up of wrinkles. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 6 collagen facial cleanser, Sunmax 7 collagen essence, Sunmax 8 active collagen essence mask, Sunmax 9 collagen refining cream, Sunmax 10 collagen eye renewal cream, Sunmax 11 collagen moisturizing cream, Sunmax 15 Collagen MesoRepair, and Sunmax Collagen Peptide that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is based in Tainan City, Taiwan.

Sunmax Biotechnology Co., Ltd.
© 2022 All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.